Global Seasonal Affective Disorder Market, by Type (Fall & Winter Seasonal Affective Disorder, Spring & Summer Seasonal Affective Disorder, and Others), by Treatment (Light Therapy, Medications, Psychotherapy, Counselling, and Others), by End User (Hospitals, Clinics, Research Institutes, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 544.7 million in 2020 and is expected to exhibit a CAGR of 5.5% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Prevalence of bipolar disorders are boosting the market growth
Rising prevalence of bipolar disorders are boosting the seasonal affective disorder, which is expected to boost the market growth. For instance, according to the Institute for Health Metrics and Evaluation (IHME), Global Burden of Diseases, in December 2017, the share of global population with bipolar disorder in 2017 was 0.6% (46 million), amongst which 0.55% were males and 0.65% were females.
Global Seasonal Affective Disorder Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 67.21 million infected individuals worldwide, as of December 8, 2020.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.
Moreover the COVID-19 pandemic has impacted the supply of raw materials and potent compounds, which are used for manufacturing drugs such as seasonal affective disorder treatment drugs, this is expected to hamper the market growth in the near future.
Browse 42 Market Data Tables and 38 Figures spread through 195 Pages and in-depth TOC on “Seasonal Affective Disorder Market – by Type (Fall & Winter Seasonal Affective Disorder, Spring & Summer Seasonal Affective Disorder, and Others), by Treatment (Light Therapy, Medications, Psychotherapy, Counselling, and Others), by End User (Hospitals, Clinics, Research Institutes, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027”
To know the latest trends and insights prevalent in the global seasonal affective disorder market, click the link below:
https://www.coherentmarketinsights.com/market-insight/seasonal-affective-disorder-market-4333
Rising prevalence of depression are boosting the seasonal affective disorder market, which is expected to boost the market growth. For instance, according to the Institute for Health Metrics and Evaluation (IHME), Global Burden of Diseases, in December 2017, the share of global population with depression in 2017 was 3.4% (264 million), amongst which 2.7% were males and 4.1% were females.
Key Takeaways of the Global Seasonal Affective Disorder Market:
- The global seasonal affective disorder market is expected to exhibit a CAGR of 5.5% during the forecast period, owing to rising incidence of seasonal affective disorder. For instance, according to an article published by the Mental Health America, Inc., in 2020, reports that about 5% of the U.S. population experience seasonal depression.
- Among type, fall & winter seasonal affective disorder segment held a dominant position in the seasonal affective disorder market in 2019, owing to increasing cases of fall & winter seasonal affective disorder. For instance, according to an article published by the Hindawi Publishing Corporation- Depression Research and Treatment, in December 2015, reports that 15% people of Canada experience sub-syndromal type of SAD, winter blues.
- Among treatment, light therapy segment held a dominant position in the seasonal affective disorder market in 2019, as light therapy offers better results. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that 60-80% of seasonal affective disorder patient are benefitted from light therapy.
- Among end user, hospitals segment held a dominant position in the seasonal affective disorder market in 2019, as hospital registration for seasonal affective disorder are highest.
- Key players operating in the global seasonal affective disorder market include Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., AbbVie, Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Mylan, Inc., Bausch Health, Koninklijke Philips N.V., Bayer AG, Allergan, Bristol-Myers Squibb, and Henry Schein Inc., among others.
